Live Markets
Saturday, September 12, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Lakefront Biotherapeutics NV (GLPGF)

PNK · Biotechnology

$48.70+14.70 (+43.24%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$3.19B
P/E (TTM)
4.64
EPS
$10.49
Div Yield
52W Range
$26.20–$34.00
Beta
0.12

Company overview

Next earnings: 2026-11-12(62d)

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

196 employeeslakefrontbio.com

Peers in Healthcare

Lakefront Biotherapeutics NV has no peer companies in this window.

Recent press releases

March 2026

5 months ago6-K

GALAPAGOS NV — 6-K Filing

GLPGFGALAPAGOS NV

# 🔥 What This Document Is This is a **6-K report** from Galapagos NV, a Belgian biotech company listed on Euronext and NASDAQ (ticker: GLPG). It’s a current report used to announce major events to investors. This specific filing announces a new, binding collaboration deal with pharmaceutical giant

Read summaryView on SEC EDGAR
5 months ago6-K

GALAPAGOS NV — 6-K Filing

GLPGFGALAPAGOS NV

# 🧾 What This Document Is This is a **6-K filing** from Galapagos NV, a Belgian biotech company. It's a "current report" filed with the SEC to inform investors of major events. This specific filing announces that Galapagos has published its **2025 Annual Report** and is calling two shareholder meet

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Lakefront Biotherapeutics NV has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
16,707,477 sh0.0%
3,921,219 sh-5.5%
349,444 sh+128.4%
339,354 sh+121.9%
1,074,112 sh-6.6%
2,213,169 sh+0.8%
1,667,119 sh0.0%
90,000 sh● NEW

People at Lakefront Biotherapeutics NV

All people →

No officers or directors have been indexed for Lakefront Biotherapeutics NV.

Quarterly financials

Full financials →
Revenue trend
12/24
NI
RevenueNI = Net Income
EPS trend (diluted)
EPS history not available.